VANCOUVER, B.C., Dec. 29, 2003 (PRIMEZONE) -- ProtoKinetix, Inc. has (OTCBB:PKTX) today satisfied the research agreement with Perigene pursuant to the Company's December 11, 2003 News Release. This contract will give ProtoKinetix, through Perigene, access to many of Europe's leading research facilities allowing the rapid development and testing of therapeutic products.
Perigene's agreement with France's University of Compiegne will allow Perigene to develop highly specific cancer therapeutic antibodies. Through this formalized relationship with Perigene, ProtoKinetix has an opportunity to commercialize the therapeutic antibodies that have been developed in the European research theatre.
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor'' for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company's filings with the Securities and Exchange Commission. Specifically, investors should be cautious as ProtoKinetix, Incorporated is presently a development stage biotechnology company with limited financial resources. Existing and prospective investors should undertake a thorough due diligence process, as well as seek advice from a registered securities broker prior to making an investment in this company.